Avacopan - ChemoCentryx

Drug Profile

Avacopan - ChemoCentryx

Alternative Names: CCX 168

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Mario Negri Institute for Pharmacological Research
  • Class Anti-inflammatories; Cyclopentanes; Piperidines; Small molecules
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Microscopic polyangiitis; Glomerulonephritis; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Wegener's granulomatosis; Haemolytic uraemic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Membranoproliferative glomerulonephritis
  • Phase II Haemolytic uraemic syndrome; IgA nephropathy
  • Clinical Phase Unknown Glomerulonephritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 07 Nov 2017 Phase-III clinical trials in Membranoproliferative glomerulonephritis (PO)
  • 07 Nov 2017 Avacopan - ChemoCentryx receives Orphan Drug status for Microscopic polyangiitis in Switzerland
  • 07 Nov 2017 Avacopan - ChemoCentryx receives Orphan Drug status for Wegener's granulomatosis in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top